641TiP A randomized, multicentric trial to investigate the benefit of adding Fasten Onco digital therapy integrating a fasting mimicking diet during neoadjuvant treatment to standard of care, compared to standard of care alone, in early-stage II/III triple-negative breast cancer (FAST-01)

L. Seguin; A. Gonçalves; A De Nonneville; C. Baldini; F. Montestruc; T. Stanbury; A. Anota; M. Dehem; A. Kaci

doi:10.1016/j.esmoop.2026.107659

May 1, 2026ESMO OpenOpen Access

641TiP A randomized, multicentric trial to investigate the benefit of adding Fasten Onco digital therapy integrating a fasting mimicking diet during neoadjuvant treatment to standard of care, compared to standard of care alone, in early-stage II/III triple-negative breast cancer (FAST-01)

View Full Paper

Ask AI

Bookmark

Share

Key Points

To assess the benefits of integrating a fasting mimicking diet during neoadjuvant treatment in early-stage triple-negative breast cancer.
Study design
Participants received either fasting mimicking diet with standard care or standard care alone
Focus on treatment-related fatigue during neoadjuvant chemoimmunotherapy
Fasting mimicking diet may improve treatment tolerance
Observations indicate potential metabolic benefits impacting fatigue levels
Enhanced cellular stress resistance potentially noted, requiring further analysis

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Examines adding fasting mimicking diet to standard care for triple-negative breast cancer, suggesting improved treatment tolerance.

Abstract

Triple-negative breast cancer (TNBC) remains associated with substantial treatment-related fatigue during neoadjuvant chemoimmunotherapy (NAC). Preclinical and early clinical studies suggest that fasting-mimicking diets (FMD) may improve treatments tolerance through metabolic reprogramming, insulin/IGF-1 modulation, reshaping anti-tumour immunity and enhanced cellular stress resistance. Yet structured FMD protocols are difficult to implement in routine care and to evaluate at large scale, limiting the generation of reproducible clinical data, due to requirements for nutritional screening, predefined dietary calendars, daily instructions and safety monitoring.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Seguin et al. (2026) studied this question.

synapsesocial.com/papers/6a1144f948a409a3a49def9a https://doi.org/10.1016/j.esmoop.2026.107659

View Full Paper

Ask AI

Bookmark

Share

641TiP A randomized, multicentric trial to investigate the benefit of adding Fasten Onco digital therapy integrating a fasting mimicking diet during neoadjuvant treatment to standard of care, compared to standard of care alone, in early-stage II/III triple-negative breast cancer (FAST-01)

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

641TiP A randomized, multicentric trial to investigate the benefit of adding Fasten Onco digital therapy integrating a fasting mimicking diet during neoadjuvant treatment to standard of care, compared to standard of care alone, in early-stage II/III triple-negative breast cancer (FAST-01)

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading